相较于2023年的一无所获,在今年的国家医保目录谈判中,被称为“魔法子弹”的ADC(抗体药物偶联物)药物终于拿下两个医保目录“席位”。其中,罗氏制药的注射用维泊妥珠单抗、第一制药三共株式会社(以下简称第一三共)/阿斯利康的注射用德曲妥珠单抗被纳入新版医保目录,而辉瑞的注射用奥加伊妥珠单抗、吉利德公司的注射用戈沙妥珠单抗则未被纳入。《每日经济新闻》记者注意到,在今年国家医保局发布医保药物目录拟调整的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.